Sarepta Therapeutics SRPT
NASDAQ SRPT
$18.74 -0.43 (-2.24%)
As of: Oct 21, 2026 · 2:25 PM EDT

Sarepta Therapeutics (SRPT) Cash from Restructuring (2016)

Updated

Sarepta Therapeutics' Cash from Restructuring came in at $407,000 for Q4 2016, up 51.3% from the prior quarter.

Analysis

Sarepta Therapeutics (SRPT) Cash from Restructuring (2016) Analysis & Trends

For FY2016, Sarepta Therapeutics' Cash from Restructuring was $911,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,135.43 Bn 1,104.02 Bn 19.71 Bn
2 Johnson & Johnson 616.54 Bn 535.06 Bn 17.26 Bn
3 AbbVie 501.55 Bn 474.66 Bn 12.70 Bn
4 Merck 367.19 Bn 321.57 Bn 12.21 Bn
5 Novartis Ag 297.91 Bn 261.90 Bn 11.24 Bn
6 Astrazeneca 261.40 Bn 235.09 Bn 12.86 Bn
7 Amgen 236.18 Bn 191.58 Bn 7.24 Bn
8 Gilead Sciences 190.55 Bn 164.75 Bn 6.22 Bn
9 Pfizer 169.40 Bn 116.05 Bn 10.94 Bn
10 Sarepta Therapeutics 1.97 Bn -1.26 Bn 251.87 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 407,000.00
Sep 30, 2016 269,000.00
API Access

Sarepta Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=SRPT&period=max&api_key=YOUR_API_KEY